A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Inclusion Criteria:

• Advanced/unresectable or metastatic solid tumor with HER2 expression or mutationthat is refractory to or intolerable with standard treatment, or for which nostandard treatment is available

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• LVEF ≥ 50% by either ECHO or MUGA

• Has adequate renal and hepatic function

• Female subjects agree not to be pregnant or lactating from beginning of the studyscreening until 6 months after receiving the last treatment

Exclusion Criteria:

• History of clinically significant lung diseases (e.g., interstitial pneumonia,pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or suspected tohave these diseases by imaging at screening period

• Known hereditary or acquired bleeding and thrombotic tendency